"The president is right to make this the center point of the rising and sustained trade conflict," says Sen. Chris Coons.Politicsread more
"We're gonna take this meeting by meeting. We're not on a preset course," Clarida told CNBC's Sara Eisen during an interview Friday on "Squawk on the Street."The Fedread more
More than 400 Chinese products will be temporarily exempted from tariffs that President Donald Trump's administration imposed last year.China Economyread more
"I feel like I've contributed all I can to this primary election," he told MSNBC's "Morning Joe." "And it's clearly not my time. So I'm going to end my presidential campaign."2020 Electionsread more
The United Auto Workers union and General Motors are making progress on their labor contract talks, however there remain "many" outstanding issues, according to a union leader...Autosread more
Democratic presidential candidate Elizabeth Warren has been given more than one opportunity over the past two weeks to clarify her response to a key question about her...Politicsread more
Apple will get a taste of whether upgraded features on the new iPhone 11 are enough to lure shoppers to retail stores around the world as the new smartphones officially hit...Technologyread more
James Bullard said he dissented on this week's Fed decision to lower rates by a quarter percentage point because he didn't think the cut was big enough.The Fedread more
Joshua Harris, Apollo Global Management's co-founder, has a message for private equity's naysayers in Washington.Delivering Alpharead more
Roku shares have more than quadrupled this year, but the stock has had some rocky days of late as more players jump into streaming.Technologyread more
Two sites were hit Saturday — the Abqaiq and Khurais oil facilities — which took out 5.7 million barrels per day of oil production.World Politicsread more
Investors should put their money in small- to mid-cap biotech stocks as rhetoric about changing the U.S. health-care system ramps up during the Democratic primary debate season, Jefferies analyst Michael Yee said Friday.
"The big biotechs have to buy the big and small biotechs, and that's where most [health-care] investors have been playing," Yee said in an interview on CNBC's "The Exchange."
Health care overall has been one of the worst-performing sectors in the stock market this year. This is in part because of concerns about 2020 Democratic proposals for "Medicare for All," which calls for eliminating private health insurance and replacing it with a universal Medicare plan.
The Health Care Select Sector SPDR Fund, an ETF that tracks the health-care industry's biggest companies, has risen by just 7% year to date as of Friday's close, significantly lagging the broader market indexes. The S&P 500 has risen 17% over that same time period.
Meanwhile, biotech stocks are outperforming. The SPDR S&P Biotech ETF is up 22% this year. Pfizer's deal last week to acquire Array Biopharma for $10.64 billion was seen as a positive sign by investors for more deals.
Still, Yee, like many other Wall Street analysts who cover the health-care sector, doesn't expect Medicare for All to be implemented.
Actually implementing Medicare for All would be tough even if a candidate like Sen. Bernie Sanders won the 2020 election, analysts say. Democrats would need to hold on to their edge in the House of Representatives and win at least three new Senate seats in the 2020 election to regain control of Congress. Then they would likely need 60 votes in the Senate and two-thirds of the House to overcome any potential filibusters.
Yee instead expects legislative reform around drug prices. "Stocks rally when that happens," he said.